Drugs / MTX110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05324501 | Oct 2022 → Sep 2024 | glioblastoma | Biodexa Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2024-10-04 | Biodexa Pharmaceuticals | Results Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma biodexapharma.com ↗
Patient #3 had progression free survival (PFS) of six months and OS thus far of 13 months since start of treatment. |
| 2024-07-02 | Biodexa Pharmaceuticals | Results Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 biodexapharma.com ↗
Although the study was not powered to reliably demonstrate efficacy, median progression free survival (PFS) was 10 months (range 8 to 20 months) and overall survival (OS) of patients in the study was 16.5 months (range 12 to 35 months). |
| 2024-02-23 | Biodexa Pharmaceuticals | Results Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update biodexapharma.com ↗
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update |
| 2024-02-08 | Biodexa Pharmaceuticals | Results Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients biodexapharma.com ↗
Patient #1 received weekly infusions of 60µM of MTX110 and survived for 12 months from the start of treatment (OS=12). |
| 2023-09-21 | Biodexa Pharmaceuticals | Results Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO) biodexapharma.com ↗
No dose-limiting toxicities have been observed at any dose level; and all study-related, non-surgical adverse events were grade 1 or 2 and correlated with the location of the lesion being treated. |
| 2023-07-06 | Biodexa Pharmaceuticals | Results Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) biodexapharma.com ↗
The study has demonstrated acceptable safety profile of the treatment (three patients reported dose-limiting toxicities) and encouraging efficacy with median overall survival (OS) of 26.1 months comparing favourably with historical data of OS of 10.0 months. |
| 2023-01-12 | Biodexa Pharmaceuticals | Results Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma biodexapharma.com ↗
Following successful completion of the first month of treatment, the DSMB reviewed the available data on 11 January 2023 and recommended dose escalation in the study to 90uM. |
| 2022-06-21 | Biodexa Pharmaceuticals | Regulatory Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma biodexapharma.com ↗
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following the submission of an application to the European Medicines Agency (“EMA”), its development programme of MTX110 for the treatment of glioma has been granted Orphan Medicinal Product designation by the agency. |
| 2022-06-01 | Biodexa Pharmaceuticals | Regulatory Fast Track Designation Granted to MTX110 Development for the Treatment of Recurrent Glioblastoma biodexapharma.com ↗
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that upon submitting an application to the U.S. Food and Drug Administration (“FDA”), its development programme of MTX110 for the treatment of recurrent glioblastoma (“rGBM”) has been granted Fast Track designation by the agency. |
| 2021-12-13 | Biodexa Pharmaceuticals | Regulatory IND Application for MTX110 Study in GBM Effective biodexapharma.com ↗
its Investigational New Drug (IND) application for a Phase 1 study of MTX110, a panobinostat complex to be administered by convection enhanced delivery in patients with recurrent glioblastoma multiforme (rGBM), has been cleared by the US FDA. |
| 2020-12-11 | Biodexa Pharmaceuticals | Results MTX110 Programmes to be presented at ISPNO 2020 biodexapharma.com ↗
1 patient progressed 8 months post treatment |
| 2020-11-24 | Biodexa Pharmaceuticals | Results MTX110 presented at 2020 Annual SNO Conference biodexapharma.com ↗
MTX110 Phase I Trial Results in DIPG and Preclinical Efficacy Data in Glioblastoma presented at 2020 Annual SNO Conference |
| 2019-10-24 | Biodexa Pharmaceuticals | Regulatory Midatech’s MTX110 Receives Orphan Designation for DIPG biodexapharma.com ↗
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has granted the Company orphan drug designation for MTX110 for the treatment of patients with Malignant Glioma, including Diffuse Intrinsic Pontine Glioma (“DIPG”), a rare and fatal form of childhood brain cancer. |
| 2019-10-15 | Biodexa Pharmaceuticals | Results Headline Results of MTX110 Phase I DIPG Study biodexapharma.com ↗
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of medicines, is pleased to announce encouraging headline results from a Phase I study at the University of California, San Francisco (“UCSF”) in patients with Diffuse Intrinsic Pontine Glioma (“DIPG”) (the “UCSF study” NCT03566199). |
All press releases naming this drug 18 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05324501 ↗ |
| Route | Other | “Weekly dosing of MTX110 via CED until progression/ unacceptable toxicity.” NCT05324501 ↗ |